Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, five have given a buy rating and one has […]
Baillie Gifford & Co Has $13 55 Million Stake in Ionis Pharmaceuticals, Inc (NASDAQ:IONS) etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.
Needham & Company LLC restated their buy rating on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $60.00 price target on the stock. A number of other research firms have also recently commented on IONS. Citigroup raised shares of Ionis […]
/PRNewswire/ Ionis Pharmaceuticals (Nasdaq: IONS) today announced that its partner Biogen presented new data highlighting the potential benefit of SPINRAZA®.
Interim results from RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma® CARLSBAD, Calif., June 30, 2023 /PRNewswire/ Ionis.